InvestorsHub Logo
Followers 143
Posts 9373
Boards Moderated 1
Alias Born 06/13/2011

Re: Hedge Starz post# 303

Wednesday, 09/14/2011 3:24:08 PM

Wednesday, September 14, 2011 3:24:08 PM

Post# of 5006
Compensated Awareness Post View Disclaimer
The short answer is stem cell-based drug rescue. Valuations are most often driven by shots on goal (drug candidates in which a company has an economic interest) in their pipeline. In the short and medium term, the drug rescue applications will remain the Company's primary focus, followed by continuing clinical development of AV-101 for neuropathic pain (VistaGen plans to license AV-101 to a larger pharmaceutical company after Phase 2) and then its cell therapy/regenerative medicine programs on a longer term basis.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VTGN News